CIK 0001581280 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 09/30
| FY2025 | FY2024 | |
|---|---|---|
| Net income (USD) | -77.7 M | -217.9 M |
| Diluted EPS (USD/shares) | -1.3 | -4.04 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-13 | 4 | PRIMARY DOCUMENT | 2026-10-09 |
| 2026-10-09 | 144 | 144 | |
| 2026-10-07 | 4 | PRIMARY DOCUMENT | 2026-10-05 |
| 2026-10-05 | 144 | 144 | |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-02 |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-02 |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-02 |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-01 |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-02 |
| 2026-10-05 | 4 | PRIMARY DOCUMENT | 2026-10-02 |
| 2026-10-02 | 144 | 144 | |
| 2026-10-02 | 144 | 144 | |
| 2026-10-02 | 144 | 144 | |
| 2026-10-02 | 144 | 144 | |
| 2026-10-02 | 144 | 144 | |
| 2026-10-02 | 144 | 144 | |
| 2026-10-01 | 144 | 144 | |
| 2026-09-25 | 4 | PRIMARY DOCUMENT | 2026-09-24 |
| 2026-09-24 | 144 | 144 | |
| 2026-09-23 | 4 | PRIMARY DOCUMENT | 2026-09-21 |
| 2026-09-23 | 4 | PRIMARY DOCUMENT | 2026-09-21 |
| 2026-09-23 | 4 | PRIMARY DOCUMENT | 2026-09-21 |
| 2026-09-21 | 144 | 144 | |
| 2026-09-21 | 144 | 144 | |
| 2026-09-21 | 144 | 144 |
Forms on file (last 1,000): 4 525, 144 334, 8-K 33, SC 13G/A 22, SCHEDULE 13G/A 21, 10-Q 12, SC 13G 8, SCHEDULE 13G 7. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=TWST (0.002 USD), /gw/filings/filings?ticker=TWST&form=8-K, /gw/filings/facts?ticker=TWST&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange